Welcome to our dedicated page for Caribou Biosciences news (Ticker: CRBU), a resource for investors and traders seeking the latest updates and insights on Caribou Biosciences stock.
Caribou Biosciences, Inc. (CRBU) is a clinical-stage biopharma leader advancing CRISPR-engineered allogeneic CAR-T cell therapies. This page aggregates official announcements, clinical trial milestones, and strategic developments related to its chRDNA technology platform.
Investors and researchers will find timely updates on Caribou's innovative pipeline programs targeting hematologic cancers and autoimmune diseases. Key focus areas include CB-010 for B-cell malignancies, CB-011 in multiple myeloma, and autoimmune applications of PD-1 knockout therapies.
The repository features press releases on clinical trial data, regulatory progress, intellectual property developments, and strategic collaborations. Content is organized to highlight scientific advancements while maintaining compliance with financial disclosure standards.
Bookmark this page for streamlined access to Caribou's latest CRISPR innovations and corporate announcements. Check regularly for updates on allogeneic cell therapy developments and their potential impact on treatment paradigms.
Caribou Biosciences (NASDAQ: CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company, announced that its President and CEO, Rachel Haurwitz, PhD, will participate in a fireside chat at the Jefferies Global Healthcare Conference. The presentation is scheduled for June 4th at 9:20 AM EDT. The webcast will be accessible through Caribou's website and will remain available for at least 30 days following the event.
Caribou Biosciences (NASDAQ: CRBU) reported Q1 2025 financial results and provided updates on its clinical programs. The company ended Q1 with $212.5 million in cash and equivalents, expected to fund operations into H2 2027. Caribou reported a net loss of $40.0 million for Q1 2025.
The company recently implemented strategic pipeline prioritization, focusing on its lead oncology programs CB-010 and CB-011, while discontinuing other trials. This resulted in a 32% workforce reduction with estimated cash payments of $2.5-3.5 million.
Key upcoming milestones include two clinical datasets in H2 2025: CB-010's ANTLER trial data from a 20-patient cohort in large B cell lymphoma, and CB-011's CaMMouflage trial data from at least 25 multiple myeloma patients at multiple dose levels.
Caribou Biosciences (NASDAQ: CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company, announced that its President and CEO, Rachel Haurwitz, PhD, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference. The presentation is scheduled for May 13th at 2:35 PM PDT. The webcast will be accessible through Caribou's website and will remain available for at least 30 days following the event.
Caribou Biosciences (CRBU) announced a strategic pipeline prioritization focusing on its lead oncology programs CB-010 and CB-011, with clinical data disclosures now planned for H2 2025. The company is implementing workforce and cost reduction initiatives, including a 32% workforce reduction, expected to extend cash runway into H2 2027.
Key updates include:
- CB-010 ANTLER trial: Plans to present data from 20-patient confirmatory cohort with 6+ months follow-up for 2L LBCL
- CB-011 CaMMouflage trial: Will share dose escalation data from minimum 25 patients with 3+ months follow-up for r/r MM
- Discontinuing GALLOP Phase 1 trial (CB-010 for lupus), AMpLify Phase 1 trial (CB-012 for AML), and preclinical research
- Reduction in force costs estimated at $2.5-3.5 million
- Preliminary cash position of $212.5 million as of March 31, 2025
Caribou Biosciences (NASDAQ: CRBU) has reported its Q4 and full year 2024 financial results, highlighting significant progress in its clinical pipeline. The company ended 2024 with $249.4 million in cash and equivalents, expected to fund operations into H2 2026.
Key financial metrics include:
- Q4 2024 revenue: $2.1 million
- Full year 2024 revenue: $10.0 million
- Q4 2024 net loss: $35.5 million
- Full year 2024 net loss: $149.1 million
The company anticipates two major clinical data releases in H1 2025: results from the ANTLER Phase 1 trial of CB-010 in second-line large B cell lymphoma and initial data from the CaMMouflage Phase 1 trial of CB-011 in relapsed/refractory multiple myeloma. The company is advancing four clinical programs across hematologic malignancies and autoimmune diseases.
Caribou Biosciences (Nasdaq: CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company, has announced its upcoming participation in two major investor conferences. Rachel Haurwitz, PhD, the company's president and CEO, will be featured in fireside chats at both events.
The schedule includes:
- H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on February 25, 2025, at 11:30 AM ET
- Leerink Global Healthcare Conference on March 11, 2025, at 1:40 PM ET
Both presentations will be available via webcast on the company's website, accessible for at least 30 days following each event.
Caribou Biosciences (CRBU) has initiated the GALLOP Phase 1 trial evaluating CB-010 in lupus patients and provided updates across its clinical programs. The company achieved significant progress in 2024, with key developments including the completion of dose level 3 in the CB-012 AMpLify trial for AML with no DLTs.
Multiple clinical data readouts are expected in H1 2025, including CB-010 ANTLER trial data in second-line and CD19 relapsed large B cell lymphoma, and CB-011 dose escalation data in multiple myeloma. The company plans to initiate a pivotal Phase 3 trial for CB-010 in H2 2025, pending confirmation of their HLA matching strategy.
With $281 million in cash as of September 30, 2024, Caribou expects to fund operations into H2 2026. The company recently strengthened its leadership team with key appointments, including Sri Ryali as CFO.
Caribou Biosciences (Nasdaq: CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Rachel Haurwitz, PhD, the company's president and CEO, will deliver a corporate update presentation on Thursday, January 16, 2025, at 10:30 am PST.
The presentation will be accessible via webcast through the Events page on Caribou's website, with recordings remaining available for 30 days following the event.
Caribou Biosciences (Nasdaq: CRBU) has appointed Sri Ryali as Chief Financial Officer, effective immediately. Ryali brings 20 years of finance and commercial experience in the biopharmaceutical industry and will lead corporate finance, investor relations, and corporate communications functions, reporting to CEO Rachel Haurwitz.
Ryali previously served as CFO of Codexis and Eiger BioPharmaceuticals, and held senior finance positions at Aimmune Therapeutics, Onyx Pharmaceuticals, and Amgen. He holds an MBA from UCLA Anderson School of Management and a BA in economics and microbiology from UCLA.
The appointment comes at a important time as Caribou advances four clinical-stage programs for hematologic malignancies and autoimmune diseases, with multiple datasets expected to be disclosed in 2025. The company focuses on developing off-the-shelf CAR-T cell therapies using CRISPR genome-editing technology.
Caribou Biosciences (Nasdaq: CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company, has announced its participation in two upcoming investor conferences. Rachel Haurwitz, PhD, the company's president and CEO, will join a panel on cell therapies in autoimmune disorders at Citi's 2024 Global Healthcare Conference in Miami on December 3 at 2:30 PM EST. She will also participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference in Coral Gables on December 4 at 10:25 AM EST. Webcasts of both events will be available on Caribou's website for 30 days following the presentations.
FAQ
What is the current stock price of Caribou Biosciences (CRBU)?
What is the market cap of Caribou Biosciences (CRBU)?
